Friday, November 21, 2008
Healthcare

 

 Focus  
 

The recently formed SMH Capital Inc. healthcare investment banking team focuses principally on "middle market" clients—companies typically with market capitalizations of $50 million to $1 billion.

The team acts as an intermediary on equity and debt financings (including private placement, PIPES and public offerings) and M&A advisory assignments for firms in all areas of healthcare, including but not limited to the following sectors: 

 
 

Life Sciences
Biotechnology
Diagnostics
Drug Delivery
Medical Devices
Nutritionals

OTC Products
Pharmaceuticals
Specialty Pharmaceuticals

Services
Alternative Site
Assisted Research
Back Office Operations

Contract Research Organizations
Facility-Based Service Businesses

Hospital Management
Information Technology
Long Term Care
Managed Care


Medical Education
Pharmaceutical Services
Revenue Cycle Management

Staffing

       
  Experienced Team

 

 Prior to joining SMH Capital, this seasoned team has completed over 200 transactions valued in excess of $60 billion for clients that include: 
   
 

Capital Raises

Alliance Pharmaceutical ($47.3 MM)
Applied Analytical Industries ($49.7 MM)
Capital Senior Living ($139.7 MM)
Community Health Systems ($100 MM)
HBO & Company ($248 MM)
Healthcare Realty Trust ($122.6 MM)
Human Genome Sciences ($118.1 MM)
Hybridon ($57.5 MM)
ICN Pharmaceuticals ($115 MM)
ICN Pharmaceuticals ($200 MM)
Innotech, Inc ($30 MM)
Interneuron Pharmaceuticals ($117 MM)
Kendle International ($49.4 MM)
Kendle International ($58 MM)
Landec ($38.6 MM)
Manor Care ($150 MM)
Marion Merrell Dow ($512 MM)
National Health Laboratories ($396 MM)
Neurex Corporation ($78 MM)
Neurex Corporation ($14 MM)
PAREXEL ($70.4 MM)
Pharmaceutical Product Development ($41.4 MM)
Progenitor ($20.1 MM)
Sequana Therapeutics ($37.1 MM)
Serologicals ($54.6 MM)
SmithKline Beecham ($1.2 MM)
United Payors & Providers ($30 MM)
Wellcome PLC ($1.1 B)

M&A Transactions

Alan James Group/Interleukin Genetics ($18.3 MM)
Applied Bioscience Int’l/PPD  ($483 MM)
Applied Immune Sciences/Rhone Poulenc Rorer  ($350 MM)
Bristol-Myers/Squibb ($12.5 B)
CellPro/Corange International ($220 MM)
Cetus/Chiron ($660 MM)
Country House (Greenalls Group)/BUPA ($102 MM)
Eastman Kodak/Sterling Drug ($5.1 B)
Forstmann Little/Community Health Systems ($1.3 B)
Genentech/Roche ($3.5 B)
Genetics Institute/American Home Products ($667 MM)
Millennix/IT&E International (now Averion) ($10 MM)
Multicare/Genesis Healthcare, Texas Pacific Group, Cypress Group ($1.4 B)
Multicare/ADS Group ($100 MM)
Multicare/Concord Health Group ($114 MM)
Orthopedic Services/NovaCare ($250.0 MM)
SmithKline Beecham/Human Genome Sciences ($125 MM)
SPI Pharmaceuticals/ICN Pharmaceuticals ($500 MM)
Sterling Drug/Sanofi ($3.5 B)
Sun Healthcare Group/Regency Healthcare ($589 MM)
Teva Pharmaceutical/Biocraft Laboratories ($356 MM)
Teva Pharmaceutical/Copley Pharmaceutical ($220 MM)
       
  Contact

 

  
 

Peter J. Mixter
Managing Director, Group Head - Healthcare
SMH Capital Investment Banking
New York, New York
(212) 893-1104
Peter.Mixter@smhcapital.com


Mitchell S. Stern
Managing Director, Healthcare
SMH Capital Investment Banking
New York, New York
(212) 893-1158
Mitch.Stern@smhcapital.com